Key Pharmacy Recalls Hydroxo-B12 Injections Due to Sterility Concerns
Key Pharmacy and Compounding Center is recalling specific lots of Hydroxo-B12 injections because the firm cannot guarantee the products are sterile.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, and the hazard involves a lack of assurance of sterility in an injectable drug, which poses a significant risk of serious injury or hospitalization if contaminated.
Plain-English summary
Key Pharmacy and Compounding Center is recalling specific lots of Hydroxo-B12 30ml PBF MDV (Calif) 1mg/mL injections. The recall involves 2 vials of the prescription-only medication prepared by the firm. The affected lots are identified by the codes t02-06-2017@102 and t02-16-2017@106, both with an expiration date of 4/30/2017.
The recall was initiated due to a lack of assurance of sterility. The firm is recalling these sterile compounded drugs while they are within their expiration dates because it cannot guarantee that the products are free from microbial contamination.
The affected products were distributed nationwide in the U.S.A., as well as in Australia and Canada. Consumers and healthcare providers should check their inventory for these specific lot numbers and stop using the product if it matches the recalled description.
The recalled product
- Product
- HYDROXO-B12 30ML PBF MDV (CALIF) 1MG/ML INJ, Injection, 1mg/mL, Rx only, 30 mL Glass/Multiple Dose vial, Prepared by Key Compounding Pharmacy
- Manufacturer
- Key Pharmacy and Compounding Center
- Category
- Drug — Compounded Injectable
- Affected units
- 2
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot # t02-06-2017@102
- Exp 4/30/2017
- t02-16-2017@106
- Exp 4/30/2017.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 79 recalled by Key Pharmacy and Compounding Center under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 79 products in this recall →Related recalls
Same manufacturer · Key Pharmacy and Compounding Center
See all →- SevereKey Pharmacy Recalls Pyridoxal-5-Phosphate Injection Due to Sterility Concerns
FDA (Drugs) · 2017-05-24
- SevereKey Pharmacy Recalls Sterile Compounded Injection Due to Sterility Concerns
FDA (Drugs) · 2017-05-24
- HighKey Pharmacy Recalls Vitamin D3 Injection Due to Sterility Concerns
FDA (Drugs) · 2017-05-24
- SevereKey Pharmacy Recalls 5-MTHF Injections Due to Sterility Concerns
FDA (Drugs) · 2017-05-24
- SevereKey Pharmacy Recalls Folic Acid Injection Due to Sterility Concerns
FDA (Drugs) · 2017-05-24
Same hazard · sterility
See all →- HighFDA recalls injectable compounded mixture in single-use syringes
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SevereHydroxocobalamin Injectable Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2014-01-22
- SevereRXQ Compounding Recalls Hydroxocobalamin Injections Due to Sterility Concerns
FDA (Drugs) · 2019-08-14
- SevereHydroxocobalamin Injection Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2015-09-23
- HighHydroxocobalamin Compounded Injections Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2022-07-20
- SevereRed Mountain Compounding Recalls S-Hydroxocobalamin Injection Due to Sterility Concerns
FDA (Drugs) · 2019-11-13
- SevereHydroxocobalamin Injection Recalled for Sterility Assurance Concerns
FDA (Drugs) · 2015-09-23